1. EA Fradinger and G Bitan (2005) En route to early diagnosis of Alzheimer’s disease – are we there yet? Trends Biotech., 23: 531-533.
  2. BH Monien, LG Apostolova, and G Bitan (2006) Early diagnostics and therapeutics for Alzheimer’s disease - how early can we get there? Expert Rev. Neurotherapeutics. 6: 1293-1306.
  3. G Bitan (2006) Structural study of metastable amyloidogenic protein oligomers by Photo-Induced Cross-linking of Unmodified Proteins (PICUP). Methods Enzymol. 413: 217-236.
  4. A Shanmugam, BH Monien, and G Bitan (2008) Development in Diagnostic and Therapeutic Strategies for Alzheimer’s Disease. In: Sun M-K, Ed. Research Progress in Alzheimer’s Disease and Dementia. Vol. 3. Nova Science Publisher, Inc. pp. 193-250.
  5. MM Condron, BH Monien, and G Bitan (2008) Synthesis and purification of highly hydrophobic peptides derived from the C-terminus of amyloid β-protein. Open Biotechnol, J., 2: 87-93.
  6. EA Fradinger, BH Monien, B Urbanc, A Lomakin, M Tan, H Li, SM Spring, MM Condron, L Cruz, C-W Xie, GB Benedek, and G Bitan (2008) C-terminal peptides co-assemble into Aβ42 oligomers and protect neurons against Aβ42-induced neurotoxicity. Proc. Natl. Acad. Sci. USA, 105: 14175–14180.
  7. F Rahimi, A Shuanmugam, and G Bitan (2008) Structure–Function Relationships of Pre-Fibrillar Protein Assemblies in Alzheimer's Disease and Related Disorders. Curr. Alz. Res. 5: 319-341.
  8. F Rahimi, P Maiti, and G Bitan (2009) Photo-Induced Cross-Linking of Unmodified Proteins (PICUP) Applied to Amyloidogenic Peptides. J. Vis. Exp., 23,, doi: 10.3791/1071.
  9. H Li, F Rahimi, K Murakami, P Maiti, S Sinha, and G Bitan (2009) Amyloids and protein aggregation –analytical methods. In Encyclopedia of Analytical Chemistry, S1-S3, RA Meyers, Ed. Chichester, UK, John Wiley & Sons Ltd., pp. 635-666.
  10. C Wu, SL Bernstein, M Murray, MM Condron, G Bitan, MT Bowers, and J-E Shea (2009) Structural characterization of Amyloid β-protein C-terminal fragments. J. Mol. Biol., 387: 492-501.
  11. 32. SL Bernstein, NF Dupuis, ND Lazo, T Wyttenbach, MM Condron, G Bitan, DB Teplow, J-E Shea, BT. Ruotolo, CV. Robinson, and MT Bowers (2009) Amyloid-β protein oligomerization and the importance of tetramers and dodecamers in the aetiology of Alzheimer’s disease. Nat. Chem. 1: 326-331.
  12. F Rahimi, K Murakami, JL Summers, C-HB Chen and G Bitan (2009) RNA aptamers generated against oligomeric Aβ40 recognize common amyloid aptatopes with high sensitivity. PLoS ONE, 4, e7694. doi:10.1371/journal.pone.0007694.
  13. H Li, BH Monien, EA Fradinger, B Urbanc and G Bitan (2010) Biophysical Characterization of Aβ42 C-terminal Fragments—Inhibitors of Aβ42 Neurotoxicity. Biochemistry, 49: 1259-1267.
  14. P Maiti, A Lomakin, GB Benedek and G Bitan (2010) Despite its role in assembly, methionine 35 is not necessary for amyloid β-protein toxicity. J. Neurochem. 113: 1252-1262.
  15. F Rahimi and G Bitan (2010) Selection of Aptamers for Amyloid β-Protein, the Causative Agent of Alzheimer’s Disease, J. Vis. Exp. 39,, doi: 10.3791/1955.
  16. H Li, BH Monien, A Lomakin, R Zemel, EA Fradinger, M Tan, SM Spring, B Urbanc, C-W Xie, GB Benedek, and G Bitan (2010) Mechanistic Investigation of the Inhibition of Aβ42 Assembly and Neurotoxicity by Aβ42 C-terminal Fragments. Biochemistry, 49: 6358-6364.
  17. P Maiti, R Piacentini, C Ripoli, C Grassi, and G Bitan (2010) Surprising assembly and toxicity behavior of amyloid β-protein oxidized to sulfone. Biochem. J., 433: 323-332.
  18. K Hochdörffer, J März-Berberich, L Nagel-Steger, M Epple, W Meyer-Zaika, A Horn, H Sticht, S Sinha, G Bitan, and T Schrader (2011) Rational Design of β-Sheet Ligands against Aβ42-induced toxicity. J. Am. Chem. Soc., 133: 4348–4358.
  19. B Urbanc, M Bentel, L Cruz, H Li, EA Fradinger BH Monien, and G Bitan (2011) In silico study of Aβ1−42 oligomer formation in the presence of Aβ-derived toxicity inhibitors. J. Mol. Biol., 410: 316–328.
  20. S Sinha, DHJ Lopes, Z Du, ES Pang, A Shanmugam, A Lomakin, P Talbiersky, A Tennstaedt, K McDaniel, R Bakshi, P-Y Kuo, M Ehrmann, GB Benedek, JA Loo, F-G Klärner, T Schrader, C Wang, G Bitan (2011) Lysine-specific molecular tweezers are broad-spectrum inhibitor of aggregation and toxicity of amyloid proteins. J. Am. Chem. Soc., 133: 16958–16969Featured in Chemical & Engineering News.
  21. J Moskovitz, P Maiti, DHJ Lopes, DB Oien, A Attar, T Liu, S Mittal, J Hayes, and G Bitan (2011) Induction of methionine-sulfoxide reductases protects neurons from amyloid β-protein insults in vitro and in vivo. Biochemistry, 50: 10687–10697.
  22. H Li, Z Du, DHJ Lopes, EA Fradinger, C Wang, and G Bitan. C-terminal Tetrapeptides Inhibit Aβ42-induced Neurotoxicity Primarily Through Specific Interaction at the N-terminus of Aβ42. (2011) J. Med. Chem., 54: 8451-8460.
  23. MM Gessel, C Wu, H Li, G Bitan, J-E Shea, and MT Bowers (2012) Aβ(39-42) Modulates Aβ Oligomerization but not Fibril Formation. Biochemistry, 51: 108-117.
  24. T Liu and G Bitan (2012) Modulating self-assembly of amyloidogenic proteins as a therapeutic approach for neurodegenerative diseases — strategies and mechanisms. ChemMedChem, 7: 359-374.
  25. F Rahimi and G Bitan (2012) The structure and function of fibrillar and oligomeric assemblies of amyloidogenic proteins. In: Pre-fibrillar amyloidogenic protein assemblies—common cytotoxins underlying degenerative diseases. F Rahimi and G Bitan, Eds. Springer Science+Media B.V., Dordrecht. pp. 1-36.
  26. H Li, R Zemel, DHJ Lopes, BH Monien, and G Bitan (2012) A two-step strategy for SAR studies of N-methylated Aβ42 C-terminal fragments as Aβ42 toxicity inhibitors. ChemMedChem, 7: 515-522.
  27. DHJ Lopes, S Sinha, C Rosensweig, and G Bitan. Application of Photochemical Cross-linking to the Study of Oligomerization of Amyloidogenic Proteins (2012) Methods Mol. Biol. 489: 11-22.
  28. C Rosensweig, K Ono, K Murakami, DK Lowenstein, G Bitan, and DB Teplow. Preparation of stable amyloid β-protein oligomers of defined assembly order (2012) Methods Mol. Biol. 489: 23-31.
  29. P Novick, DHJ Lopes, K Branson, A Esteras-Chopo, IA Graef, G Bitan, and VS Pande (2012) Design of Aβ42 aggregation inhibitors from a predicted structural motif. J. Med. Chem., 55: 3002–3010.
  30. S Prabhudesai, S Sinha, A Attar, A Kotagiri, AG Fitzmaurice, R Lakshmanan, MI Ivanova, JA Loo, F-G Klärner, T Schrader, G Bitan*, and J Bronstein* (2012) A Novel "Molecular Tweezer" Inhibitor of α-Synuclein Neurotoxicity in Vitro and in Vivo. Neurotherapeutics, 9: 464-476. *Co-corresponding authors. “Most Widely Discussed Paper” on Springer’s “#NeuroStars!” Read the press release.
  31. JM Ringman, AT Fithian, K Gylys, JL Cummings, G Coppola, D Elashoff, D Pratico, J Moskovitz, and G Bitan (2012) Plasma methionine sulfoxide in persons with familial Alzheimer's disease mutations. Dement. Geriatr. Cogn. Disord., 33: 219-225.
  32. I Solomonov, E Korkotian, B Born, D Kaganovich, Y Feldman, A Bitler, AF Rahimi, H Li, G Bitan, and I Sagi (2012) Zn2+-Aβ complexes form metastable quasi-spherical oligomers that are cytotoxic to cultured hippocampal neurons. J. Biol. Chem., 287: 20555-20564.
  33. S Sinha, Z Du, P Maiti, F-G Klärner, T Schrader, C Wang, and G Bitan (2012) Comparison of three amyloid assembly inhibitors – the sugar scyllo-inositol, the polyphenol epigallocatechin gallate, and the molecular tweezer CLR01. ACS Chem. Neurosci., 3: 451-458.
  34. S Sinha, DHJ Lopes, and G Bitan (2012) A key role for lysine residues in amyloid β-protein folding, assembly, and toxicity. ACS Chem. Neurosci., 3: 473-481. “Most-read” paper in the 2nd quarter of 2012.
  35. A Attar, C Ripoli, E Riccardi, P Maiti, DD Li Puma, T Liu, J Hayes, MR Jones, K Lichti-Kaiser, F Yang, GD Gale, C-H Tseng, M Tan, C-W Xie, JL Straudinger, F-G Klärner, T Schrader, SA Frautschy, C Grassi, and G Bitan (2012) Protection of primary neurons and mouse brain from Alzheimer’s pathology by molecular tweezers. Brain, 135: 3735-3748Read the press release.
  36. C Ripoli, R Piacentini, E Riccardi, L Leone, G Bitan, and C Grassi (2013) Effects of different forms of amyloid β-protein in rodent hippocampal neurons and brain slices. Neurobiol. Aging, 34: 1032–1044.
  37. A Attar, F Rahimi and G Bitan (2013) Modulators of amyloid protein aggregation and toxicity: EGCG and CLR01. Translational Neurosci., 4: 385-409.
  38. CR Connors, DJ Rosenman, DHJ Lopes, S Mittal, G Bitan, A Garcia, and C Wang (2013) Tranilast Binds to Aβ Monomers and Promotes Aβ Fibrillation. Biochemistry, 52: 3995-4002.
  39. A Attar, T Liu, W-T C Chan, J Hayes, M Nejad, K Lei, and G Bitan (2013) A Shortened Barnes Maze Protocol Reveals Memory Deficits at 4-Months of Age in the Triple-Transgenic Mouse Model of Alzheimer’s Disease. PLoS ONE, 8: e80355, doi: 10.1371/journal.pone.0080355.
  40. F Rahimi and G Bitan (2014) Methods for studying and structure–function relationships of non-fibrillar protein assemblies in Alzheimer's disease and related disorders. In: Advances in Alzheimer Research. Vol. 2, DK Lahiri Ed. Bentham Scientific. Pp. 291-374.
  41. S Acharya, B Safaie, P Wongkongkathep, MI Ivanova, A Attar, F-G Klärner, T Schrader, JM Loo, G Bitan, and LJ Lapidus (2014) Molecular Basis for Preventing α-synuclein Aggregation by a Molecular Tweezer. J. Biol. Chem., 289: 10727-10737Read the press release.
  42. A Attar and G Bitan (2014) Disrupting Self-Assembly and Toxicity of Amyloidogenic Protein Oligomers by “Molecular Tweezers” – from the Test Tube to Animal Models. Curr. Pharm. Des., 20: 2469-2483.
  43. A Attar, W-TC Chan, F-G Klärner, T Schrader, and G Bitan (2014) Safety and pharmacological characterization of the molecular tweezer CLR01. BMC Pharm. Tox., 15: 23, doi:10.1186/2050-6511-15-23.
  44. N Ferreira, A Pereira-Henriques, A Attar, F-G Klärner, T Schrader, G Bitan, MJ Saraiva, and MR Almeida (2014) Molecular Tweezers Targeting Transthyretin Amyloidosis. Neurotherapeutics, 11: 450-461.
  45. A Attar, D Meral, B Urbanc, and G Bitan (2014) Assembly of amyloid β-protein variants containing familial Alzheimer’s disease-linked amino acid substitutions. In: Bionanoimaging: Protein Misfolding & Aggregation. V Uversky and Y Lyubchenko Eds. Elsevier/Academic Press. Pp. 429–442.
  46. X Zheng, D-Y Liu, F-G Klärner, T Schrader, G Bitan, and MT Bowers (2015) Amyloid β-protein Assembly: The Effect of Molecular Tweezer CLR01 and CLR03. J. Phys. Chem. B, 119: 4831-4841ACS Editor's Choice.
  47. DHJ Lopes, A Attar, G Nair, EY Hayden, Z Du, K McDaniel, S Dutt, K Bravo-Rodriguez, S Mittal, F-G Klärner, C Wang, E Sanchez-Garcia, T Schrader, and G Bitan (2015) Molecular tweezers inhibit islet amyloid polypeptide assembly and toxicity by a new mechanism, ACS Chem., 10: 1555-1569.
  48. G Herzog, MD Shmueli, L Levi, L Engel, E Gazit, F-G Klärner, T Schrader, G Bitan, and D Segal (2015) The Lys-specific molecular tweezer, CLR01, modulates aggregation of mutant p53 DNA binding domain and inhibits its toxicity, Biochemistry, 54: 3729–3738. Featured in Chemical Research in Toxicology - Spotlight.
  49. E Lump, LM Castellano, C Meier, J Seeliger, N Erwin, B Sperlich, CM Stürzel, S Usmani, RM Hammond, J von Einem, G Gerold, F Kreppel, K Bravo-Rodriguez, T Pietschmann, VM Holmes, D Palesch, O Zirafi, D Weissman, A Sowislok, B Wettig, C Heid, F Kirchhoff, T Weil, F-G Klärner, T Schrader, G Bitan, E Sanchez-Garcia, R Winter, J Shorter, and J Münch (2015) A molecular tweezer antagonizes seminal amyloids and HIV infection, eLife, 2015; 4: e05397Read the Press Release.
  50. R Malishev, S Nandi, S Kolusheva, Y Levi-Kalisman, F-G Klärner, T Schrader, G Bitan*, and R Jelinek* (2015) Toxicity inhibitors protect lipid membranes from disruption by Aβ42, ACS Chem. Neurosci., 6: 1860-1869. *Co-corresponding authors.
  51. R Roychaudhuri, X Zheng, A Lomakin, P Maiti, MM Condron, GB Benedek, G Bitan, MT Bowers, and DB Teplow (2015) Role of species-specific primary structure differences in Aβ42 assembly and neurotoxicity, ACS Chem. Neurosci. 6: 1941-1955.
  52. X Zheng, C Wu, D Liu, H Li, G Bitan, J-E Shea and MT Bowers (2015) Mechanism of C-Terminal Fragments of Amyloid β-Protein as Aβ Inhibitors: C-Terminal Interactions Play a Key Role in Their Inhibitory Activity, J. Phys. Chem. B, 119: 4831-41.
  53. SM Fogerson, AJ van Brummen, DJ Busch, SR Allen, R Roychaudhuri, SM Banks, F-G Klärner, T Schrader, G Bitan, and JR Morgan (2016) Reducing synuclein accumulation improves neuronal survival after spinal cord injury, Exp. Neurol. 278: 105-115.
  54. F Rahimi, H Li, S Sinha, and G Bitan (2016) Modulators of Amyloid β-Protein (Aβ) Self-Assembly. In: Developing Therapeutics for Alzheimer's Disease: Progress and Challenges, Wolfe, M.S. Ed. Elsevier/Academic Press. Pp. 97-191.
  55. A Lulla, L Barnhill, G Bitan, M Ivanova, B Nguyen, K O’Donnel, M Stahl, C Yamashiro, F-G Klärner, T Schrader, A Sagasti, and JM Bronstein (2016) Neurotoxicity of the Parkinson's Disease-Associated Pesticide Ziram is Synuclein-Dependent in Zebrafish Embryos, Environ. Health Perspect., 124: 1766-1775Read the Press Release.
  56. H Li, F Rahimi, and G Bitan (2016) Modulation of amyloid β-protein (Aβ) assembly by homologous C-terminal fragments as a strategy for inhibiting Aβ toxicity. ACS Chem. Neurosci. 7: 845-856.
  57. T Schrader, G Bitan, and F-G Klärner (2016) Molecular Tweezers for Lysine and Arginine – Powerful Inhibitors of Pathologic Protein Aggregation. Chem. Commun. 52: 11309-11317.
  58. EY Hayden, JL Conovaloff, A Mason, G Bitan, and DB Teplow (2016) Preparation of pure populations of covalently stabilized amyloid β-protein oligomers of specific sizes. Anal. Biochem., 518: 78-85.
  59. F Richter, I Magen, P Lee, S Subramaniam, J Hayes, A Attar, C Zhu, N Franich, N Bove, K De La Rosa, J Kwong, F-G Klärner, T Schrader, M- F Chesselet, and G Bitan (2017) A molecular tweezer ameliorates motor deficits in mice overexpressing α-synuclein. Neurotherapeutics, 14: 1107-1119Read the Press Release.
  60. R Malik, J Di, G Nair, A Attar, K Taylor, E Teng, F-G Klärner, T Schrader, and G Bitan (2018) Using molecular tweezers to remodel abnormal protein self-assembly and inhibit the toxicity of amyloidogenic proteins. Methods Mol. Biol. 1777: 369-386.
  61. EY Hayden, JL Conovaloff, A Mason, G Bitan, and DB Teplow. Preparation of pure populations of amyloid β-protein oligomers of defined size (2018) Methods Mol. Biol., 1779: 3-12.
  62. RS Atlasi, R Malik, CI Corrales, L Tzeplaeff, J Whitelegge, N Cashman, and G Bitan (2018) Investigation of anti-SOD1 antibodies yields new structural insight into SOD1 misfolding and surprising behavior of the antibodies themselves. ACS Chem. Biol., 13: 2794–2807.
  63. R Malik, H Meng, P Wongkongkathep, CI Corrales, N Sepanj, SR Atlasi, F-G Klärner, T Schrader, MJ Spencer. JA Loo, M Wiedau-Pazos, and G Bitan (2019) The molecular tweezer CLR01 inhibits aberrant superoxide dismutase 1 (SOD1) self-assembly in vitro and in the G93A-SOD1 mouse model of ALS. J. Biol. Chem., 294, 3501-3513.
  64. Z Yan, S Dutta, Z Liu, X Yu, N Mesgarzadeh, F Ji, G Bitan* and Y-H Xie* (2019) A Label-free Platform for Unambiguous Cell-specific Identification of Exosomes. ACS Sensors, 4, 488-497Equal contribution. *Co-corresponding authors.
  65. C Despres, J Di, F-X Cantrelle, Z Li, I Huvent, B Chambraud, J Zhao, J Chen, S Chen, G Lippens, F Zhang, R Linhardt, C Wang, F-G Klärner, T Schrader, I Landrieu, G Bitan*, and C Smet-Nocca* (2019) Major differences between the self-assembly and seeding behavior of heparin-induced- and in-vitro-phosphorylated tau and their modulation by potential inhibitors. ACS Chem. Biol. 14: 1363-1379.  Equal contribution. *Co-corresponding authors. Watch the Live Slides.
  66. M Herrera-Vaquero, D Bouquio, M Kallab, K Biggs, G Nair, J Ochoa, W Poewe, GK Wenning, F-G Klärner, T Schrader, G Bitan*, and N Stefanova* (2019) The molecular tweezer CLR01 ameliorates the pathological phenotype in a transgenic model of multiple system atrophy. BBA-Mol. Basis Dis. 1865 (11) 165513Equal contribution. *Co-corresponding authors.
  67. EY Hayden, J Putman, S Nunez, WS Shin, M Oberoi, M Charreton, S Dutta, Z Li, Y Komuro, MT Joy, G Bitan, A MacKenzie-Graham, L Jiang, and JD Hinman (2019) Ischemic axonal injury up-regulates MARK4 in cortical neurons and primes tau phosphorylation and aggregation. Acta Neuropathol. Commun. 7: 135.
  68. WS Shin, J Di, Q Cao, B Li, PM Seidler, KA Murray, G Bitan, and L Jiang (2019) Amyloid β-protein oligomer promote the uptake of tau fibril seeds potentiating intracellular tau aggregation. Alz Res. Ther., 11: 86.
  69. G Bitan (2019) Disease-modifying therapy for proteinopathies—can the exception become the rule? In: Progress in Molecular Biology and Translational Science, Molecular Biology of Neurodegenerative Diseases: Visions for the Future. D. Teplow Ed. Elsevier/Academic Press. Pp. 277-287.
  70. S Hornung, S Dutta, and G Bitan (2020) Brain-derived blood exosomes as a promising source of biomarkers: opportunities and challenges. Frontiers Mol. Neurosci., 13: 38.
  71. AJ Mason*, I Hurst*, R Malik, I Solomonov, I Sagi, F-G Klärner, T Schrader, and G Bitan (2020) Different inhibitors of Aβ42-induced toxicity have distinct metal-ion dependency. ACS Chem. Neurosci. 11: 2243–2255. *Equal contribution.
  72. R Malik*, C Corrales*, M Linsenmeier, H Alalami, N Sepanj, and G Bitan (2020) Examination of SOD1 aggregation modulators and their potential toxicity in vitro. FASEB J. 34: 11957-11969. *Equal contribution.
  73. N Bengoa-Vergniory, E Faggiani, P Ramos-Gonzalez, E Kirkiz, N Connor-Robson, LV Brown, I Siddique, Z Li, S Vingill, M Cioroch, F Cavaliere, S Threlfell, B Roberts, T Schrader, F-G Klärner, S Cragg, B Dehay, G Bitan, C Matute, E Bezard and R Wade-Martins (2020) CLR01 protects dopaminergic neurons in vitro and in vivo in human neurons and mouse models of Parkinson’s. Nat. Commun., 11: 4885.
  74. J Di*, I Siddique*, Z Li, G Malki, S Hornung, S Dutta, I Hurst, E Ishaaya, A Wang, S Tu, A Boghos, I Ericsson, F-G Klärner, T Schrader, and G Bitan (2021) The molecular tweezer CLR01 improves behavioral deficits and reduces tau pathology in P301S-tau transgenic mice. Alz. Res. Ther., 13: 6. *Equal contribution.
  75. S Dutta, S Hornung, A Kruayatidee, KN Maina, I del Rosario, KC Paul, D Wong, A Duarte Folle, D Markovic, J-A Palma, GE Serrano, CH Adler, SL Perlman, WW Poon, UJ Kang, RN Alcalay, M Sklerov, KH Gylys, H Kaufmann, BL Fogel, JM Bronstein, B Ritz, and G Bitan (2021) α-Synuclein in blood exosomes immunoprecipitated using neuronal and oligodendroglial markers distinguishes Parkinson’s disease from multiple system atrophy. Acta Neuropathol., 142: 495-511. Read the press release.
  76. Z Li, I Siddique, I Hadrović, A Kirupakaran, J. Li, Y. Zhang, F-G Klärner, T Schrader, and G Bitan (2021) Lysine-selective molecular tweezers are cell-penetrant a concentrate in lysosomes. Commun. Biol., 4: 1076.
  77. H Shahpasand-Kroner, J Portillo, C Lantz, PM Seidler, N Sarafian, JA Loo, and G Bitan (2021) Three-repeat and four-repeat tau isoforms form different oligomers. Prot. Sci., 31: 613-627.
  78. JA Palma, J Martinez, P Millar Vernetti, T Ma, MA Perez, J Zhong, Y Qian, S Dutta, KN Maina, I Siddique, G Bitan, B Ades-Aron, TM Shepherd, UJ Kang, and H Kaufmann (2021) mTOR inhibition with sirolimus in multiple system atrophy: a randomized, double-blind, placebo-controlled futility trial and 1-year biomarker longitudinal analysis. Mov. Disord., 37:778-789.
  79. HB Taha, B Kearny, and G Bitan (2022) A minute fraction of a-synuclein in extracellular vesicles may be a major contributor to α-synuclein spreading following autophagy inhibition. Frontiers Mol. Neurosci., 15, DOI:
  80. KN Maina, C Smet-Nocca, and G Bitan (2023) Using FRET-Based Biosensor Cells to Study the Seeding Activity of Tau and α-Synuclein. Methods. Mol. Biol. 2551: 125-145.
  81. H Shahpasand-Kroner*, I Siddique*, R Malik, G Linares, MI Ivanova, J Ichida, T Weil, J Münch, E Sanchez-Garcia, F-G Klärner, T Schrader and G Bitan (2023) Molecular tweezers - supramolecular hosts with broad-spectrum biological applications. Pharmacol. Rev. DOI: *Equal contribution.




  1. L Carol (2006) Scientists focus on precursors to amyloid plaque in Alzheimer disease. Neurology Today 6: 20.
  2. W Wolfson (2008) Unraveling the Tangled Brain of Alzheimer’s. Chemistry & Biology Innovations 15: 89-90.
  3. E Landhuis (2010) Tau Oligomer Antibodies Relieve Motor Deficits in Mice. Alzheimer Research Forum Nov 25th, 2010.
  4. E Landhuis (2010) Flexible N-Termini Key to Aβ42 Oligomer Toxicity? Alzheimer Research Forum Dec 14th, 2010.
  5. A Attar, G Bitan, and H Li (2010) Invited commentary by Alzforum on paper of the week by Ladiwala et al., in J. Biol. Chem. (Nov. 23rd 2010) Aromatic small molecules remodel toxic soluble oligomers of amyloid β through three independent pathways. Dec 29th, 2010. - %7B47CEF98F-8BC1-4A37-ACA0-6E09FFCD273F%7D.
  6. G Bitan (2012) Can We Accelerate the Path towards Therapy for Amyloid-Related Diseases? J. Gerontol. Geriatr. Res. 1: e106. doi:10.4172/jggr.1000e106.
  7. Arielle Duhaime-Ross (2013) Discovery of distinct peptides in brains of Alzheimer’s patients could help diagnosis. Nature blog Sep 12th, 2013.
  8. G Bitan (2013) Invited commentary by Alzforum on paper of the week by Watt et al., in Acta Neuropathol. (Jan. 25th 2013) Oligomers, fact or artifact? SDS-PAGE induces dimerization of β-amyloid in human brain samples. Feb 14th, 2013.
  9. Hamish McDougal (2013) Pfizer's ACC-001, Transition's ELND005 face Phase II safety and efficacy hurdles in Alzheimer's – neurologists. BioPharm Insight, December 2013.
  10. Hamish McDougal (2013) Prana's PBT2 may clear amyloid-beta for Phase II Alzheimer's success though relevance questioned – experts. BioPharm Insight, December 2013.
  11. G Bitan (2014) Clear the way to healthy ageing. UCLOUD,
  12. Madolyn Bowman Rogers (2015) Do Extended Species of Aβ Poison Synapses, Masquerade As Dimers? Alzheimer Research Forum May 2nd, 2015.
  13.  Madolyn Bowman Rogers (2015) Enter Aη: Alternative APP Cleavage Creates Synaptotoxic Peptide. Alzheimer Research Forum August 31st, 2015.
  14. Thor Benson (2015) Researchers in Australia Announce Alzheimer's Breakthrough. ATTN: December 27th, 2015.
  15. G Bitan (2020) The recent failure of the PROMESA clinical trial for multiple system atrophy raises the question—are polyphenols a viable therapeutic option against proteinopathies? Ann. Trans Med., 8(11):719. doi: 10.21037/atm.2020.01.117.